Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

B. Riley Securities Resumes Lantheus Holdings at Buy with $102 PT, Views as 'Best Positioned for Success,' Notes 'Impressive' H1 PYLARIFY Sales

08/25/2022 | 09:39am EST


ę MT Newswires 2022
All news about LANTHEUS HOLDINGS, INC.
12/08Lantheus Holdings, Inc. : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
12/06Lantheus Holdings Prices $500 Million Convertible Senior Notes Offering
MT
12/06Lantheus Holdings, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
12/06Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senio..
GL
12/05Sector Update: Healthcare Stocks Slide Monday but Outperform Most Sectors
MT
12/05Sector Update: Health Care Stocks Pulled Lower by Sinking Biotechs
MT
12/05Lantheus Holdings Shares Drop 10% After Planned Senior Notes Offering
DJ
12/05Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday
MT
12/05Lantheus Holdings Plans to Offer $500 Million of Convertible Notes
MT
12/05Lantheus Holdings, Inc. : Entry into a Material Definitive Agreement, Termination of a Mat..
AQ
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 917 M - -
Net income 2022 200 M - -
Net Debt 2022 - - -
P/E ratio 2022 18,9x
Yield 2022 -
Capitalization 3 669 M 3 669 M -
Capi. / Sales 2022 4,00x
Capi. / Sales 2023 3,55x
Nbr of Employees 612
Free-Float 97,6%
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 53,31 $
Average target price 101,67 $
Spread / Average Target 90,7%
EPS Revisions
Managers and Directors
Mary Anne Heino Chief Commercial Officer
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Director
Simon Robinson Senior VP-Research & Pharmaceutical Development
Bela S. Denes Vice President-Medical Affairs
Sector and Competitors